News Sentiment

XOMA sentiment intelligence

XOMA Royalty Corporation news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 40.17 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy

74/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-9.2% over one week, -4.1% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Form 13D/A XOMA Royalty Corp For: 16 July By Investing.com

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy 74/100 classification
One-week reaction -9.2% Price reacting lower
Trend fit Trend active -4.1% over four weeks
Fair value 50.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 18
Neutral 37
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 20
Market source 11
GlobeNewswire 4
simplywall.st 3
TradingView 2
Benzinga 2
MarketBeat 2
MSN 2

Event Lens

What the news is about

Classified themes
Deals and strategy 23
Market update 18
Earnings 14
Capital return 2
Analyst action 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 60
The Pharma Letter Direct company coverage

Ligand to acquire XOMA Royalty

Tone
Neutral 50/100
Event
Market update
Published
28 Apr 2026 07:00
Source
The Pharma Letter
GlobeNewswire Direct company coverage

Ligand to Acquire XOMA Royalty, Further Accelerating Profit

Ligand Pharmaceuticals has announced its definitive agreement to acquire XOMA Royalty Corporation for approximately $739 million in cash at $39.00 per share. This acquisition is expected to significantly expand Ligand's royalty portfolio to over 200 assets, including seven new co

Tone
Positive 72/100
Event
Deals and strategy
Published
28 Apr 2026 05:08
Source
GlobeNewswire
Moomoo Direct company coverage

Ademi LLP Investigates Whether XOMA Royalty Corporation Is Obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating whether XOMA Royalty Corporation is securing a fair price for its public shareholders in its proposed transaction. The firm is examining if XOMA's board and management have upheld their fiduciary duties and if the transaction terms are equitable. Public

Tone
Negative 39/100
Event
Market update
Published
28 Apr 2026 05:08
Source
Moomoo
Benzinga Direct company coverage

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Ligand Pharmaceuticals is acquiring XOMA Royalty for over $700 million, aiming to significantly expand its biopharma royalty portfolio and enhance long-term growth. The acquisition, valued at $39.00 per share in cash, is expected to be immediately accretive to Ligand's adjusted E

Tone
Positive 76/100
Event
Deals and strategy
Published
27 Apr 2026 17:38
Source
Benzinga
Stock Titan Direct company coverage

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Ligand Pharmaceuticals (LGND) will acquire XOMA Royalty (XOMA) for $39.00 per share in cash, totaling approximately $739 million, plus a non-transferable Contingent Value Right (CVR) per share tied to potential litigation proceeds. This acquisition is expected to add seven market

Tone
Positive 72/100
Event
Deals and strategy
Published
27 Apr 2026 16:39
Source
Stock Titan
Benzinga Direct company coverage

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

XOMA Royalty, Oruka Therapeutics, and Repay Holdings were among several stocks that saw significant gains on Monday. XOMA Royalty surged after Ligand Pharmaceuticals announced plans to acquire it for $39.00 per share, while Oruka Therapeutics and Veradermics Inc rallied on positi

Tone
Positive 81/100
Event
Market update
Published
27 Apr 2026 14:10
Source
Benzinga
PR Newswire Direct company coverage

Shareholder Alert: Ademi LLP investigates whether XOMA Royalty Corporation is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating XOMA (NASDAQ: XOMA) for potential breaches of fiduciary duty related to its recently announced transaction with Ligand. The firm is examining whether the $39.00 per share cash price, totaling approximately $739 million plus a contingent value right, rep

Tone
Negative 37/100
Event
Balance sheet
Published
27 Apr 2026 14:10
Source
PR Newswire
Reuters Direct company coverage

Ligand Pharma to acquire fellow biotech royalty rights buyer XOMA for $739 million

Ligand Pharmaceuticals announced its acquisition of XOMA Royalty for approximately $739 million in cash. This deal will add over 120 treatments to Ligand's portfolio, including seven marketed products, boosting its total to more than 200 drugs. Ligand expects the acquisition to b

Tone
Positive 76/100
Event
Deals and strategy
Published
27 Apr 2026 12:12
Source
Reuters
Stock Titan Direct company coverage

Ligand to buy XOMA Royalty (Nasdaq: XOMA) in $739M cash and CVR deal

Ligand Pharmaceuticals has agreed to acquire XOMA Royalty Corporation for approximately $739 million, with XOMA stockholders receiving $39.00 per share in cash plus contingent value rights (CVRs) tied to potential proceeds from Janssen-related litigation. This deal offers XOMA sh

Tone
Positive 70/100
Event
Deals and strategy
Published
27 Apr 2026 12:10
Source
Stock Titan
Business Wire Direct company coverage

XOMA Stock Alert: Halper Sadeh LLC is Investigating Whether XOMA Royalty Corporation is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the sale of XOMA Royalty Corporation (NASDAQ: XOMA) to Ligand Pharmaceuticals Incorporated for $39.00 per share. The firm is examining whether XOMA and its board of directors failed to obtain the best possible price

Tone
Negative 30/100
Event
Market update
Published
27 Apr 2026 12:10
Source
Business Wire
MarketBeat Direct company coverage

XOMA Royalty (NASDAQ:XOMA) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?

XOMA Royalty (NASDAQ:XOMA) stock recently traded above its 200-day moving average, reaching $40.15 before settling at $39.37. The company beat quarterly earnings and revenue expectations with a significant net margin, leading to a "Moderate Buy" consensus from analysts, who proje

Tone
Positive 72/100
Event
Earnings
Published
24 Apr 2026 03:09
Source
MarketBeat
MSN Direct company coverage

HC Wainwright & Co. maintains XOMA Royalty (XOMA) buy recommendation

This article states that HC Wainwright & Co. has reiterated its buy recommendation for XOMA Royalty (XOMA). No additional details are provided in the current content.

Tone
Positive 71/100
Event
Market update
Published
23 Apr 2026 15:38
Source
MSN
Stock Titan Direct company coverage

XOMA (XOMA) CEO Owen Hughes exercises 10,568 PSUs and updates holdings

XOMA Royalty Corp CEO Owen Hughes exercised 10,568 Performance Stock Units (PSUs) on April 20, 2026, receiving an equal number of common stock shares. Following this transaction, his direct holdings increased to 191,264 common shares, with an additional 295 indirectly held throug

Tone
Neutral 50/100
Event
Market update
Published
22 Apr 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

XOMA (XOMA) CFO converts 11,538 Performance Stock Units into common shares

XOMA Royalty Corp's CFO, Jeffrey Trigilio, converted 11,538 Performance Stock Units (PSUs) into an equal number of common shares on April 20, 2026, at an exercise price of $0.00 per share. Following this transaction, Mr. Trigilio directly holds 103,906 shares of common stock and

Tone
Neutral 50/100
Event
Market update
Published
22 Apr 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

XOMA (XOMA) legal chief converts 3,370 PSUs into common shares

XOMA Royalty Corp's Chief Legal Officer, Maricel Perea Montano, converted 3,370 Performance Stock Units (PSUs) into common shares on April 20, 2026, at $0.00 per share. This transaction increased her direct holdings to 41,793 common shares, with 37,074 PSUs remaining outstanding

Tone
Neutral 50/100
Event
Market update
Published
22 Apr 2026 20:10
Source
Stock Titan
Intellectia AI Direct company coverage

XOMA Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for Xoma Royalty Corp (XOMA). It indicates a 'Strong Buy' overall technical sentiment based on a combination of moving averages and oscillators, despite some indicators suggesting a 'Sell' condition due to the st

Tone
Positive 75/100
Event
Guidance
Published
22 Apr 2026 17:10
Source
Intellectia AI
Stock Traders Daily Direct company coverage

How (XOMAP) Movements Inform Risk Allocation Models

This article analyzes Xoma Corporation's (NASDAQ: XOMAP) stock movements and provides three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging) tailored for different risk profiles. It highlights conflicting sentiment across various time horizons, sugg

Tone
Neutral 50/100
Event
Market update
Published
16 Apr 2026 18:08
Source
Stock Traders Daily
Stock Titan Direct company coverage

XOMA (XOMA) CFO exercises 4,000 PSUs, 1,632 shares withheld for taxes

XOMA Royalty Corp's CFO, Jeffrey Trigilio, exercised 4,000 Performance Stock Units (PSUs), converting them into 4,000 common shares. To cover tax obligations, 1,632 shares were withheld through a non-open market transaction at $36.76 per share. Following these transactions, Trigi

Tone
Neutral 50/100
Event
Market update
Published
16 Apr 2026 00:39
Source
Stock Titan
MarketBeat Direct company coverage

XOMA Royalty Corporation (NASDAQ:XOMA) Receives Average Rating of "Moderate Buy" from Brokerages

XOMA Royalty Corporation (NASDAQ:XOMA) has received an average "Moderate Buy" rating from six brokerages, with an average 12-month price target of $61.60. Despite beating earnings estimates in its last quarter, analysts forecast a negative EPS for the current fiscal year. Institu

Tone
Positive 64/100
Event
Earnings
Published
15 Apr 2026 11:39
Source
MarketBeat
MSN Direct company coverage

Turnstone Biologics to be acquired by XOMA Royalty

The article states that Turnstone Biologics is set to be acquired by XOMA Royalty. No further details about the acquisition or the companies involved are provided.

Tone
Positive 72/100
Event
Deals and strategy
Published
14 Apr 2026 09:09
Source
MSN
Stock Traders Daily Direct company coverage

Understanding Momentum Shifts in (XOMAO)

This article provides an AI-driven analysis of Xoma Corporation Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock (NASDAQ: XOMAO), highlighting a neutral near-term sentiment with a mid-channel oscillation pattern. It outlines three distinct trading strategies—posit

Tone
Neutral 50/100
Event
Market update
Published
13 Apr 2026 13:54
Source
Stock Traders Daily
Stock Titan Direct company coverage

XOMA SEC Filings - XOMA Royalty Corporation 10-K, 10-Q, 8-K Forms

This page provides access to SEC filings for XOMA Royalty Corporation (XOMA), including 10-K, 10-Q, 8-K, and Form 4 documents, enhanced with AI-powered summaries. Recent filings detail Q3 2025 financial results, an updated tender offer for LAVA Therapeutics, "at the market" sales

Tone
Positive 60/100
Event
Earnings
Published
05 Apr 2026 13:08
Source
Stock Titan